Stephen V. Frye Ph.D.
Professor, Division of Medicinal Chemistry and Natural Products
Director, Center for Integrative Chemical Biology and Drug Discovery
Eshelman School of Pharmacy The University of North Carolina at Chapel Hill
Stephen Frye is Professor and Director of the Center for Integrative Chemical Biology and Drug Discovery at UNC-Chapel Hill. His research focuses on oncology drug discovery and the chemical biology of chromatin regulation. Before joining UNC in 2007, he served as worldwide Vice President for High Throughput and Discovery Medicinal Chemistry at GlaxoSmithKline. During his 20 years at GSK, his creation and leadership of a department focused on oncology and protein kinases resulted in the discovery of several drugs, one of which has been approved for the treatment of metastatic breast cancer and another that is in Phase III trials for kidney cancer. He is also the inventor of Avodart, GlaxoSmithKline’s drug used for treatment of benign prostate disease, which is currently under investigation for the prevention of prostate cancer. Frye earned his BS in chemistry at North Carolina State University and his PhD in organic chemistry at UNC-Chapel Hill.
Talk Title: “Promoting illiteracy in epigenetics: antagonists of the readers of the epigenetic code”